Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of HHT120 in Healthy Subjects
NCT05414734Phase 1Withdrawn
- Sponsor
- Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HHT120 in venous thromboembolism (VTE) (6 arms), sponsored by Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Primary endpoints: Vital signs, Physical examination and 5 more. Planned start Jul 2022; status: withdrawn.
02
Drugs
HHT120
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05414734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05414734.